Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms.
Brilinta: +84%, with continued momentum in the US and Europe.
Diabetes: +128%, following successful integration of BMS assets and strong US Farxiga launch.
Respiratory: +9%, driven by US Symbicort growth of 25%.
Emerging Markets: +11%, with China growth of 23%.
Japan: +1%, impacted by biennial price decreases.
Core EPS in the second quarter was $1.30, up 13%. Half year Core EPS declined 1%.
Almirall deal offers multiple benefits and long-term value to AstraZeneca's respiratory franchise, a key growth platform and an area of strategic priority.
Immediate and growing product revenues with earnings accretion from 2016.
Enhances portfolio in asthma and COPD with novel bronchodilators.
Significant progress made towards achieving scientific leadership.
14 projects in Phase III, up from 8 a year ago.
Strong data presented at ATS for respiratory biologics assets; at ASCO for immuno-oncology portfolio and AZD9291, olaparib and cediranib, and at ADA for saxagliptin and dapagliflozin combination.
The Company increases its revenue and Core EPS guidance for the full year.
Revenue is expected to be in line with 2013 at CER, an increase on our previous guidance of low-to-mid single digit percentage decline.
Core EPS is expected to decrease in low double digits at CER, an update on our previous guidance of a percentage decrease in the teens.
o For planning purposes, revenue and Core EPS guidance assumes US Nexium generic enters on 1 October 2014.
o The Company continues to pursue multiple productivity initiatives and redeploy resources to fund its pipeline and growth platforms, whilst managing its total cost base.
The Board has recommended a first interim dividend of $0.90.